Scholarlink

<p>Transarterial radioembolization using radionuclide-labeled microspheres has shown efficacy in the treatment of hepatocellular carcinoma (HCC). In this study, a novel formulation of Polyvinyl alcohol-collagen microspheres (PCMs) with an optimal settling rate is developed. Fourier-transform infrared spectroscopy (FTIR) and scanning electron microscopy (SEM) analyses confirm that the PCMs have uniform morphology with diameters ranging from 20 to 30&#xa0;μm. These microspheres are successfully labeled with <sup>131</sup>I, exhibiting good in vitro stability. Subsequently, <sup>131</sup>I-labeled PCMs are administered via the hepatic artery into rats with orthotopic HCC, leading to a significant increase in median overall survival (<i>p</i> &lt; 0.05). Single photon emission computed tomography (SPECT/CT) imaging and immunohistochemical assessments demonstrate precise biodistribution and stable retention of <sup>131</sup>I-PCMs in the liver for up to 14 days. Magnetic resonance imaging (MRI) further reveals the inhibition of tumor growth following <sup>131</sup>I-PCM treatment. In summary, the <sup>131</sup>I-PCMs display high radiolabeling efficiency, stability, and a promising radioembolization effect in the orthotopic HCC rodent model, highlighting their potential for use in interventional cancer therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preparation of iodine-131 labeled Polyvinyl alcohol-collagen microspheres for radioembolization therapy of liver tumors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月14日

查看全文
  • Yuhao Li,
  • Huawei Cai,
  • Yikai Xing,
  • Fuwen Pang,
  • Lin Li

摘要

Transarterial radioembolization using radionuclide-labeled microspheres has shown efficacy in the treatment of hepatocellular carcinoma (HCC). In this study, a novel formulation of Polyvinyl alcohol-collagen microspheres (PCMs) with an optimal settling rate is developed. Fourier-transform infrared spectroscopy (FTIR) and scanning electron microscopy (SEM) analyses confirm that the PCMs have uniform morphology with diameters ranging from 20 to 30 μm. These microspheres are successfully labeled with 131I, exhibiting good in vitro stability. Subsequently, 131I-labeled PCMs are administered via the hepatic artery into rats with orthotopic HCC, leading to a significant increase in median overall survival (p < 0.05). Single photon emission computed tomography (SPECT/CT) imaging and immunohistochemical assessments demonstrate precise biodistribution and stable retention of 131I-PCMs in the liver for up to 14 days. Magnetic resonance imaging (MRI) further reveals the inhibition of tumor growth following 131I-PCM treatment. In summary, the 131I-PCMs display high radiolabeling efficiency, stability, and a promising radioembolization effect in the orthotopic HCC rodent model, highlighting their potential for use in interventional cancer therapy.